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Systemic sclerosis (SSc) is frequently associated with interstitial lung disease (ILD) often
leading to lung fibrosis. In this study we investigated whether matrix metalloproteinase 9
(MMP-9) and its natural inhibitor; the tissue inhibitor of matrix metalloproteinase 1 (TIMP-1),
would be associated with remodelling in ILD in SSc.
Levels of total MMP-9, pro-MMP-9 and TIMP-1 were measured in bronchoalveolar lavage
(BAL) fluid from nine SSc patients with ILD, seven SSc patients without ILD and 16 age- and
sex-matched healthy controls.
Total MMP-9 and pro-MMP-9 levels were significantly elevated in SSc patients with ILD,
compared to levels in SSc patients without ILD and healthy controls. In SSc patients with ILD
calculated active MMP-9 levels were significantly higher than in SSc patients without ILD and
tended to be higher than in healthy controls. TIMP-1 levels were elevated in both patient
groups compared to healthy controls. Total-, pro- and active MMP-9 levels as well as pro-
MMP-TIMP-1 and active MMP-9/TIMP-1 ratios were inversely associated with total lung
capacity.Elsevier Ltd. All rights reserved.
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G.N. Andersen et al.2200The present study suggests that MMP-9 plays a pathophysiological role in the remodelling in
ILD and lung fibrosis associated with SSc, and may represent a new therapeutic target in this
condition.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Interstitial lung disease (ILD) has been found in 75% of
systemic sclerosis (SSc) cases at autopsy.1 ILD may develop in
both limited (lcSSc) and diffuse cutaneous scleroderma
(dcSSc) and is associated with decreased survival.2,3
Extensive ILD is, however, far more common in dcSSc and
often associated with the presence of anti scleroderma-70
antibodies (anti Scl-70 Ab).4 The pathogenesis of ILD in
association with SSc is unclear and the current treatment
unspecific.
The histopathology of ILD in SSc is often characterised by
remodelling and thickening of alveolar septal interstitiae
with lose or dense fibrosis, foci of tissue degradation
with honeycombing and lymphocyte infiltration.5 The
histology correlates to the findings by high resolution
computed tomography (HRCT) of the lungs,6 and ILD in
SSc is conveniently diagnosed by this method, which
permits imaging of the lung parenchyma in detail.4 Apart
from reported elevated levels of neutrophil elastase7
and mast cell tryptase8 in bronchoalveolar lavage (BAL) in
SSc, it is unclear what enzymes may be involved in
extracellular matrix (ECM) degradation and remodelling in
ILD in SSc.
The matrix metalloproteinases (MMPs) are a family of
zinc- and calcium-dependent endopeptidases that have the
ability to degrade all major connective tissue matrices.
MMP-9, a type IV collagenase, also called gelatinase B
because of its ability to break down gelatin, has substrate
specificity for a variety of ECM constituents such as native
collagens IV and V, gelatin, elastin and vitronectin9 and has
been observed to play an important role in lung tissue
remodelling in an experimental model of lung fibrosis.10 In
man, increased MMP-9 production has been found in several
lung diseases, characterised by the degradation and
remodelling of lung interstitial tissue and airways. As
collagen IV is an important constituent of alveolar and
bronchial basement membranes, MMP-9 is considered to
play an important role in the development of the histo-
pathologic changes found in idiopathic lung fibrosis,11,12
emphysema,13 chronic obstructive lung disease (COPD),14,15
the acute respiratory distress syndrome (ARDS)16,17 and
asthma.18,19 Extracellular control of MMP-9 activity is mainly
accomplished by the tissue inhibitor of metalloproteinases 1
(TIMP-1).
MMP-9 is produced constitutively by neutrophils and
eosinophils,20,21 stored in granules and immediately re-
leased in the pro-form upon chemokine stimulation.22 In
mast cells,23 monocytes and lymphocytes,24 MMP-9 synthesis
is induced by inflammatory mediators and released with
certain latency.
Neutrophils are incapable of TIMP-1 production,22 but
eosinophils,21 mast cells18 monocytes/macrophages19 and
fibroblasts,25 synthesise TIMP-1 upon cytokine stimulation.Complexed as well as unbound TIMP-1 is susceptible to the
degradation by serine proteases released from activated
neutrophils20 and mast cells.26 Excess unbound TIMP-1 may
play a role in the generation of fibrosis, promoting fibroblast
proliferation.27
Since an increased number of neutrophils7,28,29 is the
hallmark of BAL fluid changes in ILD in SSc, and as
eosinophil-30 and mast cell numbers often are elevated,8
an increased airway secretion of MMP-9 and TIMP-1 was
anticipated. Based on these considerations, we hypothe-
sised that MMP-9 and TIMP-1 may play essential roles in ECM
remodelling in ILD in SSc. To investigate this, we measured
levels of MMP-9 and TIMP-1 in BAL fluid from SSc patients
with signs of ILD on HRCT, in SSc patients with normal HRCT
and in healthy controls and related these levels to lung
function.Patients and methods
The characteristics of the patients and controls are given in
Table 1. Sixteen consecutive patients (13 women and 3 men)
with SSc according to the American College of Rheumatology
(formerly the American Rheumatism Association) criteria31
were studied. Twelve of the patients (11 women and one
man) had lcSSc and four (two women and two men) had
dcSSc.32 Three of the patients with lcSSc (all female) also
fulfilled the Alarcon-Segovia and Cardiel criteria for mixed
connective tissue disease (MCTD).33 At the time of investi-
gation, six patients with lcSSc had anti-centromere anti-
bodies, one with lcSSc and two with dcSSc had anti-Scl-70 Ab
and all three, who fulfilled the criteria for MCTD, had high-
titer anti-RNP antibodies.
Signs of ILD on HRCT of the lungs were found in nine
of the 16 SSc patients, that is in six of the 12 patients (50%)
with lcSSc and in three of the four patients (75%) with
dcSSc. Anti-Scl-70 antibodies were present in three of the
nine SSc patients with signs of ILD on HRCT and in none
of the seven SSc patients with normal HRCT. The patients
had never smoked, except for two patients with signs of ILD
on HRCT and two SSc patients with normal HRCT, who
were ex-smokers but had not smoked for the last three
years prior to bronchoscopy. The age of the SSc patients
with signs of ILD on HRCT tended to be higher than that of
the SSc patients with normal HRCT (62.0 (13.0) (median
(interquartile range)) vs. 53.0 (14.0); P ¼ 0.06). The disease
duration tended to be shorter in SSc patients with
signs of ILD on HRCT compared to SSc with normal
HRCT (6.0 (9.3) vs. 14.0 (20.8); P ¼ 0.09), Table 1. Three
SSc patients with signs of ILD on HRCT and three SSc
patients with normal HRCT were medicated with corticos-
teroids. Sixteen age- and sex-matched healthy subjects
(who had never smoked) randomly selected from within
the age cohort in the population register of the county
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Table 1 Clinical characteristics of patients with systemic sclerosis and the control group.
Variable SSc without ILD SSc with ILD Controls
(N ¼ 7) (N ¼ 9) (N ¼ 16)
Median (IQR) Median (IQR) Median (IQR)
Age, years 53.0 (14.0) 62.0 (13.0) 57.5 (20.0)
Females/males 6/1 7/2 13/3
Disease duration, years 14.0 (20.8) 6.0 (9.3)
Limited/diffuse cutaneous SSc 6/1 6/3
Skin score 1.0 (2.0) 1.0 (4.0)
Previous scleroderma renal crisis 0 1
Oesophagus involvement 4 5
Anticentromere-/Anti-scleroderma 70/Anti-
ribonucleoprotein antibodies
4/0/1 2/3/2
FEV1 118.0 (24.9) 99.1 (29.1)
VC 121.0 (16.3) 97.5 (23.0)
TLC 117.0 (8.3) 90.7 (11.6)
DLCO 88.9 (26.9) 66.5 (31.6)
FEV1, forced expired volume during the first second; VC, vital capacity; TLC, total lung capacity; DLCO, diffusion capacity for carbon
monoxide. Lung functions are expressed in % of predicted.
P ¼ 0.0095.
Bronchoalveolar matrix metalloproteinase 9 2201of Va¨sterbotten, Sweden, served as controls. The
study was approved by the Ethics committee of Umea
University and informed consent was obtained from all study
subjects.
Bronchoscopies
Fiberoptic bronchoscopy (Olympus BF type IT200, Tokyo,
Japan) with BAL was conducted as previously outlined.34 In
summary, 3 60ml of sterile phosphate buffered saline
(PBS), pH 7.3, at 37 1C was instilled into the segmental
bronchus of the middle lobe of the right lung. The
immediately recovered aspirate was collected into a
siliconised container placed on ice.
Processing of lavage fluid and cells
The aspirated BAL fluid was passed through a nylon filter
(pore diameter 100 mm, Syntab Product AB, Malmo¨, Sweden)
and centrifuged at 400g for 15min to remove mucus
and cellular components. Supernatants were separated
from cell pellets and the cell-free fluid divided into aliquots
and stored at 80 1C prior to analysis. Cell pellets derived
from BAL were re-suspended in PBS to give a final
concentration of 106 cells/ml and total and differential
leukocyte counts performed. The total number of cells in
the lavage fluid was counted in a Bu¨rker chamber.
Cytocentrifuged specimens with 5 104 non-epithelial cells
per slide were prepared using a Cytospin 3 (Shandon
Southern Instruments Inc., Sewikly, PA, USA) 1000 rpm
(96g) for 5min. Cell differential counts were conducted on
slides stained according to May-Gru¨nwald Giemsa and 400
cells per slide were counted. Mast cells were counted in at
least 10 visual fields at  160 magnification on slides stained
with acid toluidine blue and counter stained with Mayer’s
acid haematoxylin.MMP-9
Cleavage of pro-MMP-9 near or at residue 87 results in the
active enzyme with a mass of approximately 82 kDa. Levels
of total-MMP-9 (active+pro-MMP-9) were measured by
means of an ELISA assay (R&D Systems, Oxon, UK). The
detection limit for total MMP-9 was 0.156 ng/ml.
Levels of pro-MMP-9 were analysed using an ELISA method
(Amersham Pharmacia, Buckinghamshire, UK). The values
recorded included free and complexed forms. For the pro-
MMP-9 ELISA the detection limit was 0.06 ng/ml.
Active MMP-9 values were calculated as the difference
between concentrations of total MMP-9 and pro-MMP-9.
TIMP-1
Levels of TIMP-1 were measured using an ELISA method
(Amersham Pharmacia, Buckinghamshire, UK). The values
recorded included free and MMP-bound forms.
For the TIMP-1 ELISA the detection limit was 1.25 ng/ml.
Myeloperoxidase (MPO)
MPO is released from activated neutrophils and is therefore
considered a marker of neutrophil activation. MPO was
measured by a radio-immuno assay (RIA) (Pharmacia AB,
Uppsala, Sweden). The detection limit was 8 mg/L.
Methyl-histamine
Histamine is synthesised by mast cells and basophils and
stored in secretory granules. Released histamine disappears
within minutes due to methylation via histamine-N-methyl-
transferase. Methyl-histamine was measured by RIA (Phar-
macia AB, Uppsala, Sweden). The detection limit was
0.1 mg/L.
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G.N. Andersen et al.2202Eosinophilic cationic protein (ECP)
ECP is a strikingly basic protein localised in the eosinophil
granule matrix and a member of the ribonuclease gene
superfamily. ECP was measured by RIA (Pharmacia AB,
Uppsala, Sweden). The detection limit was 1 mg/L.
Lung function assessments
Lung volumes, dynamic spirometry and diffusing capacity of
the lung for carbon monoxide (DLCO) were measured
according to standard procedures (Master Spirometer and
Master Pro Transfer; Jaeger, Wu¨rzburg, Germany).
HRCT of the lungs
HRCTof the lungs was performed using a Philips Tomoscan LX
Single slice scanner (MA, USA). Scans were performed at full
inspiration in the supine position with 120 kV, 175mAmp
including contiguous scans throughout the lungs with 10mm
thickness followed by scans with 1.5mm thickness with a
slice spacing of 30mm. Ground glass opacities, reticulate
pattern fibrosis, non-septal and/or subpleural lines and
honeycombing were considered signs of ILD.4
Statistical analysis
Results are reported as median and interquartile range
(IQR). Comparisons between the three groups (SSc patients
with ILD, SSc patients without ILD and controls) were
analysed with a non-parametric ANOVA (Kruskal–Wallis test).
A significant difference was considered at the 5% level. If a
significant change was found in a parameter using the
Kruskal–Wallis test, post-hoc analyses were performed using
Mann–Whitney U-test. The Mann–Whitney non-parametric
test was also used to compare lung function variables
between SSc patients with and without ILD. Correlation
analyses were performed using the non-parametric Spear-
man’s rank correlation test. P values less than 0.05 were
considered significant.
Results
Lung function and gas transfer
The nine patients with signs of ILD on HRCT had significantly
reduced total lung capacity (TLC), as an indicator of
restrictive lung function deterioration, compared with
patients without ILD (P ¼ 0.01). Vital capacity (VC) showed
a tendency towards a decrease in SSc patients with ILD,
although not significant (P ¼ 0.057). Neither FEV1 nor DLCO
differed between the groups (Table 1).
HRCT findings
Of the nine patients with signs of ILD on HRCT two had
ground glass changes as well as honeycombing, of these two
patients, one had ground glass changes confined to the
lower parts of the lower lobes while the other had ground
glass changes in the lower parts of all lobes. Three patientshad reticular pattern lung fibrosis with mild honeycombing
in the lower parts of the lower lobes and the remaining four
had reticular pattern lung fibrosis in the lower parts of the
lower lobes.
Total and differential cell counts in BAL fluid
The neutrophil is a key cell in airway inflammation in SSc and
although the Kruskal–Wallis test only showed a tendency
towards a significant difference in neutrophil numbers
between the three groups (P ¼ 0.085), post-hoc analyses
were carried out. The number of neutrophils was slightly
elevated in SSc patients with signs of ILD on HRCT compared
to SSc patients with normal HRCT (P ¼ 0.04) and compared
to controls (P ¼ 0.049). The number of eosinophils was
significantly higher in the nine SSc patients with signs of ILD
on HRCT compared to healthy controls (P ¼ 0.007). The
number of mast cells was significantly elevated in both SSc
patients with signs of ILD on HRCT and in SSc patients with
normal HRCT compared to healthy controls (P ¼ 0.009 and
0.008, respectively). There was no significant difference in
the volumes of BAL fluid recovered from the SSc patients and
the normal controls (Table 2).
Levels of total MMP-9, Pro-MMP-9; calculated levels
of active MMP-9. TIMP-1; pro-MMP-9/TIMP-1 and
active MMP-9/TIMP-1 ratios in BAL fluid
Total MMP-9 and pro-MMP-9 levels were significantly
increased In BAL fluid from the nine SSc patients with signs
of ILD on HRCT compared to levels in healthy controls
(P ¼ 0.012 and 0.03, respectively) and compared to levels in
SSc patients with normal HRCT (P ¼ 0.0008 for both). In SSc
patients with ILD, calculated active MMP-9 levels were
significantly higher than in SSc patients without ILD
(P ¼ 0.0012) and tended to be higher than in healthy
controls (P ¼ 0.057). In SSc patients without ILD calculated
active MMP-9 levels were significantly lower than in healthy
controls (P ¼ 0.0093). TIMP-1 levels were significantly high-
er in both the nine SSc patients with signs of ILD on HRCT
(P ¼ 0.02) and the seven SSc patients with normal HRCT
(P ¼ 0.048) compared to controls The pro-MMP-9/TIMP-1
ratio was higher in SSc patients with signs of ILD on HRCT,
compared to SSc patients with normal HRCT (P ¼ 0.005), but
did not differ significantly from the ratio found in healthy
controls (P ¼ 0.3). In SSc patients with ILD the active MMP-
9/TIMP-1 ratio was significantly higher than in SSc patients
without ILD (P ¼ 0.0070), but did not differ from healthy
controls (P ¼ 0.808). In SSc patients without ILD the active
MMP-9/TIMP-1 ratio was significantly lower than in healthy
controls (P ¼ 0.0013) (Table 3).
MPO, ECP and M-histamine in BAL fluid
As a sign of neutrophil activation, MPO levels were
significantly elevated in BAL fluid from SSc with signs of
ILD on HRCT compared to both healthy controls (P ¼ 0.004)
and SSc patients with normal HRCT (P ¼ 0.009). ECP levels
showed a tendency towards an increase in SSc with signs of
ILD on HRCT both compared to SSc with normal HRCT and to
healthy controls (P ¼ 0.03 in both; Kruskal–Wallis test
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Table 3 Soluble components in bronchoalveolar lavage fluid from 16 patients with systemic sclerosis and 16 healthy controls.
Controls SSc without
ILD
P vs.
controls
SSc with
ILD
P vs.
controls
P
comparison
between
SSc groups
P
Kruskal–
Wallis test
N ¼ 16 N ¼ 7 N ¼ 9
Median
(IQR)
Median
(IQR)
Median
(IQR)
ECPmg/L 0.9 (0.5) 1.0 (0.06) 0.8 1.8 (1.4) 0.03 0.03 0.05
MPO mg/L 3.5 (4.1) 1.6 (3.7) 0.3 6.6 (14.7) 0.004 0.009 0.009
Total MMP-9 ng/ml 1.2 (1.3) 0.6 (0.7) 0.2 3.0 (3.7) 0.012 0.0008 0.01
Pro-MMP-9 ng/ml 0.2 (0.4) 0.08 (0.05) 0.2 0.4 (0.1) 0.03 0.0008 0.009
Active MMP-9 ng/ml 1.01
(1.063)
0.620
(0.595)
0.0093 2.713
(3.746)
0.057 0.0012 0.002
TIMP-1 ng/ml 7.0 (3.3) 9.5 (4.0) 0.048 14.3 (21.1) 0.02 0.2 0.03
Pro-MMP-9/TIMP-1 0.009
(0.01)
0.002
(0.001)
0.07 0.009
(0.01)
0.3 0.005 0.02
Active MMP-9/TIMP-1 0.055
(0.055)
0.009
(0.018)
0.0013 0.064
(0.102)
0.808 0.0070 0.004
SSc, systemic sclerosis; ILD, interstitial lung disease; IQR, interquartile range; ECP, eosinophilic cationic protein; MPO,
myeloperoxidase; MMP-9, matrix metalloproteinase 9; TIMP, tissue inhibitor of metalloproteinase.
Table 2 Cellularity of bronchoalveolar lavage fluid in 16 patients with systemic sclerosis and 16 healthy controls.
Controls SSc without
ILD
P vs.
controls
SSc with
ILD
P vs.
controls
P
comparison
between
SSc groups
P
Kruskal–
Wallis test
N ¼ 16 N ¼ 7 N ¼ 9
Median
(IQR)
Median
(IQR)
Median
(IQR)
Total cells 104/ml 4.2 (2.75) 3.6 (3.7) 0.6 5.3 (7.8) 0.2 0.1 0.3006
Alveolar
macrophages 104/ml
3.3 (2.6) 2.2 (3.0) 0.9 4.0 (9.5) 0.2 0.2 0.3708
Lymphocytes 104/ml 0.7 (0.5) 0.7 (0.5) 0.6 0.8 (0.8) 0.8 0.8 0.8274
Neutrophils 104/ml 0.04 (0.1) 0.01 (0.1) 0.3 0.1 (0.2) 0.049 0.04 0.0854
Eosinophils 104/ml 0.007 (0.02) 0.03 (0.1) 0.1 0.1 (0.2) 0.007 0.08 0.0142
Mast cells 104/ml 0.0005
(0.0008)
0.0015
(0.016)
0.034 0.004
(0.017)
0.0033 0.4 0.0086
SSc, systemic sclerosis; ILD, interstitial lung disease; IQR, interquartile range.
Bronchoalveolar matrix metalloproteinase 9 22030.051). Methyl-histamine was only detectable in three
SSc patients with signs of ILD on HRCT and in no SSc patient
with normal HRCT or any of the controls (data not shown)
(Table 3).Correlation analyses
For the total group of 16 SSc patients with and without ILD,
the levels of total MMP-9, pro-MMP-9 and active MMP-9 were
significantly associated with the number of neutrophils
(rs ¼ 0.74; P ¼ 0.006 and rs ¼ 0.550; P ¼ 0.03, rs ¼ 0.711;
P ¼ 0.008, respectively). Eosinophil numbers tended tonon-significantly correlate with total MMP-9 (rs ¼ 0.494;
P ¼ 0.07) and pro-MMP-9 (rs ¼ 0.458; P ¼ 0.09) and corre-
lated significantly to levels of active MMP-9 (rs ¼ 0.544;
P ¼ 0.04).
Levels of TIMP-1 showed a trend towards a significant
association with the number of mast cells (rs ¼ 0.52;
P ¼ 0.051).
As regards the relationship between metalloprotease/
antiprotease and restrictive lung function changes, the
levels of total-MMP-9, pro-MMP-9 and the pro-MMP-9/TIMP-1
ratio were all negatively associated with TLC (rs ¼ 0.68;
P ¼ 0.01, rs ¼ 0.58; P ¼ 0.02 and rs ¼ 0.56; P ¼ 0.03,
respectively).
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Figure 1 Correlations between active MMP-9 and TLC in
percent of predicted in 16 systemic sclerosis patients. Solid
circles represent patients with interstitial lung disease.
G.N. Andersen et al.2204The corresponding correlations between active MMP-9
and reduction in TLC were rs ¼ 0.67; P ¼ 0.009 (Fig. 1) and
between active MMP-9/TIMP-1 and TLC rs ¼ 0.62;
P ¼ 0.016.Discussion
In the present study we have demonstrated that BAL fluid
levels of MMP-9 are enhanced in SSc patients with signs of
ILD on HRCT, compared to SSc patients without ILD.
Furthermore, the increased MMP-9 concentrations were
associated with a reduction in TLC, an important conse-
quence of ILD.
The study was performed in SSc patients treated in our
clinic after having given informed consent to participate in a
bronchoscopy investigation. Ideally, a very large cohort of
individuals would have been included, but availability of
patients, time for performing the study and resources set
limits. The study material is relatively similar in size to
other investigations of the field and has strength by the
matched control group.
The present data imply MMP-9 to be produced locally in
the lungs and predominantly by neutrophils. Using levels of
MPO and ECP as markers, the study indicates that
neutrophils and, to a lesser extent, eosinophils are activated
in SSc patients with signs of ILD on HRCT. Besides pointing at
the neutrophil, correlation analyses did not exclude the
eosinophil as a potential additional source of MMP-9. Upon
IL-8 stimulation, activated neutrophils release considerable
amounts of unbound MMP-9, while eosinophils and mast cells
release partly complexed MMP-9 and TIMP-1 after pro-
inflammatory cytokine stimulation. The present result is in
agreement with the previous observations of increased
BAL fluid concentrations of IL-8,28 IL-6 and TNF alpha35 in
ILD in SSc.
In this study, TIMP-1 levels were elevated in both groups
of SSc patients compared to the control subjects and showed
a tendency (P ¼ 0.051) to correlate with BAL fluid mast cell
numbers. An inherent difficulty in exploring patient groups
and controls with bronchoscopy is that the obtainablenumber of subjects is commonly low, due to the invasive
sampling procedure. It can therefore be debated whether
correction for comparison between multiple groups needs to
be applied or not. The data indicate, but do not definitely
prove that mast cells may contribute to the elevated levels
of TIMP-1 in SSc and other cellular sources cannot be
excluded.36 It has been speculated that an excess of
unbound TIMP-1 may stimulate fibroblast proliferation and
potentially enhance development of fibrosis.27 The present
study does not support this assumption as there was no
indication of excessive TIMP-1, in relationship with either
pro-MMP-9 or active MMP-9, in the SSc patients with ILD. In
contrast, patients with SSc without ILD, had more TIMP-1 in
relationship to the MMP-9 forms.
In the patient group without ILD, which comprised six
patients with lSSc, DLCO was slightly reduced, whereas TLC
was normal. Of these, one has developed severe isolated
pulmonary hypertension and two have increased pulmonary
arterial pressure measured by echocardiography. Isolated
DLCO reduction with a normal TLC is a common abnormality
in SSc due to thickening of the wall in small- and medium-
sized pulmonary arteries37 and may antedate the develop-
ment of isolated pulmonary hypertension, which is espe-
cially common in lSSc patients.38
ILD may lead to remodelling of the lung resulting in a
restrictive lung function pattern and lung fibrosis. In the
present study of patients with SSc with and without ILD, the
MMP-9 levels, regardless if expressed as total-, pro- or
active MMP-9 were all inversely associated with TLC,
consistent with a role for alveolar MMP-9 in remodelling
and lung volume reduction. Furthermore, in an inflamma-
tory environment the local degradation of the inhibitor
TIMP-1 may be accentuated due to increases in neutrophil
elastase7,30 and mast cell proteases.8,26 The more abundant
pro-MMP-9 in SSc patients with ILD may also be locally
activated by elevated levels of inducible enzymes such as
MMP-3 (stromelysin), plasmin and inflammatory cell derived
proteases.9
It is suggested that the neutrophil may play an important
role also in the regulation of the inflammatory process in ILD
in SSc which may lead to lung fibrosis, through MMP-9
production.39 MMP-9 may be able to potentiate the effects
of IL-8 and establish a positive feedback loop for neutrophil
attraction, activation and MMP-9 release.40 MMP-9 may also
activate IL-1 beta, an auto-inducible cytokine central to the
inflammatory reaction.41 Furthermore, MMP-9 has been
suggested to create neo-epitopes, which trigger T cell
activation in auto-immune diseases,42 a phenomenon desig-
nated ‘‘remnant epitopes that generate auto-immunity’’.
Considering this, treatment with MMP-9 inhibitors may, in
addition to reducing ECM degradation, inhibit auto-immune
self-perpetuating reactions in ILD in SSc.43 Such an option
that may be available in the future as a broad-spectrum MMP
inhibitor has been found to reduce experimental lung
fibrosis.44,45
In summary, the results point to an extended role for
activated neutrophils in ILD development in SSc due to
increased release of MMP-9. Bronchoalveolar levels of MMP-9
were further inversely associated with TLC, suggesting a role
of MMP-9 in the remodelling in ILD and lung fibrosis. The
metalloprotease burden in the lung in SSc with ILD may
represent a new therapeutic target in this condition.
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